CLDX

Celldex is a clinical-stage biopharma where the income statement is irrelevant and the pipeline is everything. The $1.54M 'revenue' (down 78% YoY) is residual collaboration/grant income, not product sales — management states plainly it has 'no product revenue and will need to raise capital,' and the $1.81B accumulated deficit, -$259M net loss, and -$211M operating cash flow confirm this is a pure cash-burn R&D engine (R&D itself rose 50% to $245M as trials scaled). On valuation, P/S of 1,613x and a -49% ROE are meaningless here; the only number that matters is the gap between the $2.49B market cap and the eventual commercial value of barzolvolimab.

The bull case rests on genuinely de-risked Phase 2 data, not hope. Lead asset barzolvolimab (anti-KIT) hit its primary endpoint in chronic spontaneous urticaria with statistical significance, and the 76-week follow-up is the standout: over 40% of patients sustained a profound complete response seven months *after* dosing stopped — a durability signal rare in this space. The chronic inducible urticaria Phase 2 (ColdU/SD) also met its primary and all secondary endpoints with high significance. That converts the upcoming readouts from coin-flips into better-than-even bets: Phase 3 CSU enrollment is complete with topline in Q4 2026, plus Phase 2 topline in prurigo nodularis (summer 2026) and atopic dermatitis (late 2026), and a CDX-622 bispecific readout in Q3 2026 — four shots on goal inside twelve months.